WASHINGTON, 30 AUG 2026 — ChangXin Memory Technologies, China's largest DRAM maker, has sued the US Defense Department to be removed from its list of Chinese military companies. The list is widely called a blacklist. It is not an export control, and it does not stop anyone selling to CXMT.
What the list actually does
The Section 1260H list identifies Chinese military companies operating in the United States. On its own it imposes no sanctions and no export restrictions, and it is a different instrument from the Commerce Department's Entity List, which does restrict what can be shipped to a named party.
What 1260H now carries is procurement consequence. Under Section 805 of the FY2024 defence authorisation, effective 30 June 2026, the Defense Department may not enter into, renew or extend contracts for goods, services or technology with a listed entity or an entity it controls. From June 2027 that prohibition extends to procuring goods and services produced or developed by them.
The direct legal effect is confined to the Pentagon's own purchasing. The indirect effect is what drives the lawsuit: banks, insurers, index providers and customers de-risk against the label whether a statute obliges them to or not.
The claim being made
CXMT filed in the District of Columbia on 28 August, arguing that it is not affiliated with the Chinese military and that it designs, produces and sells DRAM for civilian and commercial use. It contends the designation was arbitrary, unsupported by sufficient evidence, and made in violation of its due-process rights.
The company was designated under the Biden administration in January 2025 and kept on the list in a June update by the Trump administration. That the designation survived a change of government makes the arbitrariness argument harder to win.
Alibaba brought a comparable challenge before this one. Companies do occasionally win these cases, and the successful ones have generally turned on the adequacy of the record rather than on the merits of the underlying policy.
The same argument the Pentagon just lost
The legal theory here is nearly identical to one a US company deployed against the same department this month, with a very different reception.
Anthropic argued that a Pentagon supply-chain risk designation was arbitrary and capricious and denied it due process, and a federal judge granted a preliminary injunction blocking enforcement, though the designation itself still stands pending separate litigation.
The doctrinal question in both cases is whether a designation with real commercial consequences requires an adequate evidentiary record and a meaningful opportunity to respond. The political context is obviously not the same, and courts have been considerably more willing to police process for domestic litigants than for Chinese state-adjacent ones.
The CXMT filing is therefore a test of whether that procedural principle is applied consistently, or only as a courtesy to domestic firms.
Why a Chinese company litigates in an American court at all
A Chinese state-adjacent firm suing the Pentagon has little prospect of winning, and that reading undersells the procedural value of the filing itself.
A complaint forces a record. The government must respond, and in responding it either produces the evidence behind the designation or explains why it cannot. Either outcome is useful to the plaintiff. If the government produces evidence, it can be contested; if it does not, that supports the procedural argument.
Litigation also creates a document that customers, lenders and index committees can point to. A supplier under a designation it has not challenged is in a weaker position with a nervous counterparty than one that has filed and can show it is contesting the record.
The cost is also negligible relative to the stake. For a company scaling into a global memory shortage, a federal filing is cheap insurance against being treated as untouchable by conservative buyers.
The 874 per cent problem
CXMT reported revenue growth of 874 per cent in the first half of 2026, a figure that requires context.
Growth of that magnitude is a statement about a base, not about scale. A company can multiply revenue nearly tenfold and remain small relative to Samsung, SK Hynix or Micron, and no absolute revenue figure has been published alongside it.
The figure does establish direction. CXMT supplies DRAM into smartphones, PCs, servers and AI systems, and the memory market has been in shortage through the year, which is the most favourable possible environment for a producer scaling output. Whatever the base, the company is taking volume in a market where its competitors are constrained.
Why this matters for buyers in this region
The practical question for a hardware manufacturer or systems integrator in Southeast Asia is whether a 1260H listing restricts you from buying CXMT memory. On the plain terms of the instrument, it does not.
Two qualifications matter. If you sell into the US defence supply chain, the June 2027 extension to goods produced or developed by listed entities will reach you, and the lead time on redesigning a bill of materials is longer than the time remaining. And a listing is a signal about the direction of policy: the Entity List and 1260H have overlapping populations, and a company on one is a plausible candidate for the other.
The disciplined response is to know which list a supplier is on and what that list actually does. The difference between them is the difference between a compliance problem and a reputational one.
